We sincerely thank the 851 peer reviewers who completed manuscript reviews for JAMA Neurology in 2024.

This nonrandomized clinical trial investigates the safety, tolerance, and therapeutic potential of N-acetylcysteine in lowering disease-associated biomarkers in patients with hereditary cystatin C amyloid angiopathy.

In the Research Letter titled, “Accuracy of New John Cunningham Virus Antibody Assay in Natalizumab-Treated Patients With Multiple Sclerosis,” there were errors in the second paragraph of the Results section. The first 2 sentences of that paragraph should be as follows: “IgG test index values were higher in patients with positive results from both assays (median [range] difference, 0.17 [−0.85 to 1.01]). This difference increased after excluding 7 patients with index above 1.5 (median [range] difference, 0.19 [−0.42 to 0.59]) from the second-generation assay.” This article has been corrected online.

This Viewpoint explores how current ethical challenges of N-of-1 trials for serious neurological diseases could be addressed by integrating current approaches into learning healthcare systems.

This case report describes cerebral white matter abnormalities from encephalitis caused by Angiostrongylus cantonensis in a 60-year-old woman.

This cohort study investigates if 3-T magnetic resonance imaging paired with machine learning meets primary end points for differentiating Parkinson disease, multiple system atrophy parkinsonian variant, and progressive supranuclear palsy.

This case report describes a patient with spontaneous, arrhythmic, spasmodic contractions of the abdominal muscles whose imaging confirmed involvement of the genu, body, and splenium of the corpus callosum.

The Original Investigation titled “Neuromodulation for Children With Hemiparesis and Perinatal Stroke: A Randomized Clinical Trial,” published on February 3, 2025, was corrected to fix the spelling of Alana Ramsay’s name. This article was corrected online.

This population-based cohort study examines the association of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors with the risk of Alzheimer disease and related dementias in patients with type 2 diabetes.

In Reply We thank Yilmaz and Jankovic for their commentary on our article. They highlight 2 fundamental points that are important to consider when interpreting observational studies.

To the Editor We read with great interest the study by Neilson et al analyzing the electronic health record data of 3 596 365 veterans with an audiogram suggesting that hearing loss may increase the risk of Parkinson disease (PD). Although the study does not provide information on the prevalence of tremor in their population, we suggest that the majority of the patients had PD-related tremor, and a substantial number had coexistent essential tremor (ET). The latter is supported by growing evidence based on well-designed prospective studies that patients with ET have an increased risk of developing PD and that ET may be a prodromal feature of PD. Previous studies have found an increased incidence of hearing loss in patients with ET compared with both healthy controls and patients with PD. Indeed, 1 study reported a hearing impairment rate of 65.3% in patients with ET. It is, therefore, possible that patients with PD who also have coexistent ET, called the ET-PD syndrome, have an increased risk of hearing loss.

This observational study examines the feasibility and safety of a new preloaded robot-assisted thrombectomy system specifically designed for mechanical thrombectomy.

For years, researchers had been searching for hormones that promote insulin secretion. These hormones, known as incretins, could be the key to helping treat type 2 diabetes (T2D). In the 1980s, glucagon-like peptide-1 (GLP-1) was found to be an incretin secreted by L-cells in the small intestine and to inhibit glucagon secretion. However, because of the short half-life of GLP-1, it took decades to translate our understanding of GLP-1 into an effective medication for treating T2D. In 2005, exenatide was the first GLP-1 receptor agonist (GLP-1RA) medication that was approved by the US Food and Drug Administration (FDA) to treat T2D.

Mission Statement: The mission of JAMA Neurology is to publish and disseminate scientific information primarily important for physicians caring for people with neurologic disorders and for those interested in the structure and function of the normal and diseased human nervous system. The specific aims are to (1) publish timely original research, including clinical trials that will directly improve clinical neurologic care and that will inform efforts to improve neurological health and promote health care equity; (2) report translational research that is pertinent to the understanding of neurologic disease; (3) address topics of practice, ethics, education, and public health that are a key part of modern medicine; and (4) provide a forum for discussion and publication of important topics including bias, racism, and diversity. This information will be published only after extensive review by scientific peers and journal editors so that clarity, rigor, originality, and precision are ensured.

This case report describes a diagnosis of muscle infiltration of mycosis fungoides in a female aged 36 years with initial disease manifesting as pigmented skin patches.

This randomized clinical trial investigates if reldesemtiv slows disease progression in amyotrophic lateral sclerosis.

This meta-analysis examines the association of cardioprotective glucose-lowering agents, including glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors, with reductions in dementia and cognitive impairment.

As we look back on 2024, I want to take a moment to thank all of JAMA Neurology’s editors, our Editorial Board, authors, and peer reviewers for their tremendous contributions over the past 12 months. The time that they have all devoted to the journal, assuring that we are able to publish outstanding manuscripts, is so appreciated. The sheer scope of what has been published this year, highlighting the amazing diversity of discoveries and advances across neurology and related fields, has been quite impressive to behold.

This essay details the author’s personal experience with poison ivy itch and the synchronicity of a similar realization for a patient at his former facility.

This cross-sectional study categorizes and quantifies temporal and thematic trends in investment in neurology from 2000 to 2023.

This cross-sectional study examines the increase in positive results for John Cunningham virus antibodies and higher risk for progressive multifocal leukoencephalopathy among patients with multiple sclerosis receiving natalizumab.

This cohort study investigates if the clinical phenotype of patients without dementia is associated with blood phosphorylated tau 217 interpretation.

To the Editor We read with interest the work of Maarse et al that seeks to examine the benefit of percutaneous left atrial appendage occlusion (LAAO) in patients who have a thromboembolic event while taking anticoagulation. Using propensity matching, a comparison of a cohort of patients with LAAO with a control cohort suggests a hazard ratio (HR) of 0.33 (95% CI, 0.19-0.58). This is an improbably large effect size—far larger than the HR of 0.67 (95% CI, 0.53-0.85) from the Left Atrial Appendage Occlusion During Cardiac Surgery to Prevent Stroke (LAAOS III) trial in which the LAA was surgically removed during cardiac surgery. The design of the study may have led to an overestimation of the effect size.

This secondary analysis uses data from the placebo-controlled portions of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials to characterize amyloid-related imaging abnormalities in participants treated with donanemab with early symptomatic Alzheimer disease and elevated amyloid levels.

In Reply In their letter to the editor, Joundi and colleagues responded to our publication comparing thromboembolic risk reduction by left atrial appendage occlusion (LAAO) to continuing oral anticoagulant therapy (OAT) in patients with atrial fibrillation (AF) and a history of stroke despite OAT. Joundi and colleagues express their concerns about the high effect size of LAAO (hazard ratio [HR], 0.33; 95% CI, 0.19-0.58), which they attribute to an immortal time bias, and conclude that the true effect estimate of percutaneous LAAO remains elusive.